Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.

Zacks Equity Research

Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.

Sanghamitra Saha headshot

4 Top Stocks to Buy on Earnings Beat Potential

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).

Zacks Equity Research

Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.

Zacks Equity Research

Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.

Zacks Equity Research

IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases

by Zacks Equity Research

IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.

Zacks Equity Research

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Zacks Equity Research

Avantor (AVTR) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.

Zacks Equity Research

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.

Zacks Equity Research

CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.

Zacks Equity Research

Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised

by Zacks Equity Research

Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.

Zacks Equity Research

Accuray (ARAY) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.

Zacks Equity Research

BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down

by Zacks Equity Research

Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.

Zacks Equity Research

Hologic (HOLX) Q1 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

Lower COVID-19 assays sales and supply chain challenges related to semiconductor chips dent Hologic's (HOLX) top line in Q1.

Zacks Equity Research

McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.

Zacks Equity Research

Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Drop

by Zacks Equity Research

Align Technology's (ALGN) lower scanner volume and ASPs are partially offset by higher services revenues from the larger installed base of scanners and increased non-system revenues.

Zacks Equity Research

Hologic (HOLX) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 18.89% and 9.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

If You Invested $1000 in Hologic 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Supriyo Bose headshot

5 Stocks With High ROE to Buy as Equity Markets Hold Promise

by Supriyo Bose

Jabil (JBL), Delta Air (DAL), AGNC Investment (AGNC), Hologic (HOLX) and Suzano (SUZ) are some of the stocks with high ROE to profit from as equity markets start 2023 on a positive note.

Zacks Equity Research

Philips' (PHG) Q4 Earnings Down Y/Y, Supply Chain Issues Ease

by Zacks Equity Research

Koninklijke Philips' (PHG) Q4 top and bottom-line results reflect easing supply chain constraints.

Zacks Equity Research

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ongoing sales rebound in the base business for the Diagnostics and Drug Development segments likely drive LabCorp (LH) Q4 revenues.

Urmimala Biswas headshot

Medical Device Stocks' Earnings on Feb 1: BSX, TMO & More

by Urmimala Biswas

Medical device companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, HOLX and ALGN fare this time.